A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse
ResearchPosted on rand.org May 9, 2016Published in: Military Medicine, v. 181, no. 5, May 2016, p. 410-423
Guidance on how to prevent or treat the misuse of prescription drugs in the U.S. Department of Defense and Veterans Administration is similar to directives outside the military system, and tends to focus on opioids.
ResearchPosted on rand.org May 9, 2016Published in: Military Medicine, v. 181, no. 5, May 2016, p. 410-423
OBJECTIVES: This is a review and evaluation of the current clinical guidelines and empirical literature in relation to the Department of Defense (DoD) policies and directives regarding prescription drug misuse (PDM). METHODS: Sources were 11 clinical guidelines and consensus statements, 20 DoD Directives and the published literature from 2000 to 2012. Articles were included if they specifically focused on the prevention or treatment of PDM. RESULTS: DoD directives were evaluated in relation to the clinical guidelines and the relevant research literature. Empirical evidence supporting the directives was limited. CONCLUSIONS: There is little empirical evidence for the prevention and treatment of PDM and the majority of published guidelines and studies focus on prescription opioids. Important limitations include the lack of information about appropriately identifying and managing persons at risk for PDM. More research is needed to identify and recommend effective mechanisms for the prevention and treatment of PDM.
Policymakers and researchers should seek more data on prevention and treatment approaches to build a stronger evidence base.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.